表皮生长因子样结构域7(EGFL7)在正常子宫内膜及不良生殖结局妇女子宫内膜中的表达特征
探索性研究纳入84例子宫内膜活检,比较正常生育妇女、不明原因复发性流产(uRPL)和反复种植失败(RIF)妇女子宫内膜中EGFL7的表达。发现EGFL7在整个月经周期中高度表达于内皮和腺上皮,分泌期基质细胞上调其表达;在uRPL和RIF妇女的分泌期子宫内膜及分离的基质细胞中EGFL7显著降低,并与NOTCH1信号通路下调相关。
要点
- EGFL7在正常子宫内膜的内皮和腺上皮中高表达,分泌期较增殖期水平更高。
- uRPL和RIF妇女分泌期子宫内膜中EGFL7显著降低,伴NOTCH1信号通路下调。
- 重组EGFL7可激活正常生育妇女子宫内膜基质细胞的NOTCH1通路,但对uRPL或RIF患者的细胞无此作用。
核心结论
- EGFL7是参与蜕膜化的新因子,其表达改变及伴随的NOTCH信号失调可能是RIF和uRPL的潜在原因。
- EGFL7/NOTCH通路可能成为医学干预的潜在靶点,具有治疗相关性。
研究设计与样本
- 探索性研究,共收集84例子宫内膜活检,来自正常生育妇女、uRPL妇女和RIF妇女。
- 样本取自月经周期增殖期和分泌期,按临床病史分为三组:20例正常生育妇女(增殖期8例,分泌期12例)、41例uRPL妇女(增殖期6例,分泌期35例)、27例RIF妇女(增殖期8例,分泌期19例)。
- 采用免疫组化、实时PCR和蛋白质印迹分析研究EGFL7、NOTCH1及NOTCH靶基因的表达。
主要发现
- 正常生育妇女子宫内膜中,分泌期样本的EGFL7水平高于增殖期。
- EGFL7表达于内皮细胞,并新发现表达于子宫内膜腺体和基质细胞。
- uRPL和RIF妇女分泌期子宫内膜中EGFL7显著降低,并与NOTCH1信号通路下调相关。
- 人重组EGFL7能激活正常生育妇女子宫内膜基质细胞(EndSCs)的NOTCH1信号通路,但不能激活uRPL或RIF患者细胞的该通路。
- 正常生育妇女的EndSCs体外蜕膜化三天后EGFL7表达上调,而uRPL和RIF妇女的细胞体外蜕膜化后未上调。
局限性
- 本研究患者样本数量相对较少。
- 尽管结果高度可重复且一致,但来自多中心队列的额外观察将增强数据的重要性。
- 本研究为体外研究,可能仅部分代表体内条件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Could epidermal growth factor-like domain 7 (EGFL7) be a factor involved in the preparation of the endometrium for implantation and could its dysregulation be implicated in poor reproductive outcomes? SUMMARY ANSWER: EGFL7 is highly expressed in the endothelium and glandular epithelium throughout the menstrual cycle; it is upregulated by stromal cells in secretory phase and appears strongly reduced in endometrial biopsies and isolated stromal cells of women with unexplained recurrent pregnancy loss (uRPL) and recurrent implantation failure (RIF). WHAT IS KNOWN ALREADY: The secreted factor EGFL7, originally identified as a gene primarily expressed in endothelial cells, is also expressed by the mouse blastocyst and by mouse and human trophoblast cells. It regulates trophoblast migration and invasion by activating NOTCH1 signaling. NOTCH1 has been demonstrated to play a fundamental role in endometrial receptivity and its dysregulation may be involved in selected pregnancy complications characterized by altered endometrial receptivity, such as uRPL. STUDY DESIGN, SIZE, DURATION: This is an exploratory study for which 84 endometrial biopsies were collected from normally fertile women, as well as from women with uRPL and RIF. PARTICIPANTS/MATERIALS, SETTING, METHODS: Samples were collected from women in both the proliferative and secretory phases of the menstrual cycle and stratified into three sub-groups according to the patient clinical history: 20 fertile women (8 in proliferative and 12 in secretory phase), 41 women with uRPL (6 in proliferative and 35 in secretory phase), and 27 women with RIF (8 in proliferative and 19 in secretory phase). Immunohistochemistry, real-time PCR, and western blot analyses were performed to study the expression of EGFL7 and NOTCH1, as well as the NOTCH target genes. MAIN RESULTS AND THE ROLE OF CHANCE: Analysis of spatial and temporal distribution of EGFL7 in endometrial biopsies from fertile women revealed higher levels of EGFL7 in samples from the secretory phase compared to proliferative phase. The expected expression of EGFL7 in endothelial cells was shown as well as the novel, not previously reported, expression in endometrial glands and stromal cells. EGFL7 was significantly reduced in the endometrium of women with uRPL and RIF in the secretory phases and this was associated with a downregulation of the NOTCH1 signaling pathway. Human recombinant EGFL7 was able to activate the NOTCH1 signaling pathway in endometrial stromal cells (EndSCs) obtained from fertile women but not in cells from uRPL or RIF patients. EndSCs from fertile women and decidualized in vitro for three days showed an upregulation of EGFL7 expression, whereas cells obtained from women with uRPL and RIF and decidualized in vitro did not. LIMITATIONS, REASONS FOR CAUTION: This study was conducted with a relatively small number of patient samples. Although results are highly reproducible and consistent, additional observations from multicentric cohorts would strengthen the relevance of the data. Moreover, this is an in vitro study, which might only partially represent the in vivo conditions. WIDER IMPLICATIONS OF THE FINDINGS: Our results demonstrate for the first time that EGFL7 is new player involved in decidualization and provide new insights into the pathophysiology of selected implantation defects and early pregnancy complications. Our studies have revealed that alterations in EGFL7 expression and the consequent dysregulation of NOTCH signaling are potential underlying causes of RIF and uRPL. Our results might have therapeutic relevance, as the EGFL7/NOTCH pathway may represent a potential target for medical intervention. STUDY FUNDING/COMPETING INTEREST(S): This study has been supported by the Grant for Fertility Innovation 2017 (Merck KGaA). There are no competing interests to disclose. TRIAL REGISTRATION NUMBER: Not applicable.
引用
- Lacconi V, Massimiani M, Paglione L, et al. Characterization of epidermal growth factor-like domain 7 (EGFL7) expression in normal endometrium and in the endometrium of women with poor reproductive outcomes. Hum Reprod. 2023. PMID: 37159518. doi:10.1093/humrep/dead086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。